BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the Guggenheim 6th Annual Biotechnology Conference in New York, New York on Wednesday, February 7, 2024 at 2:00 p.m. EST. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
Fireside chat details: | ||
Date: | Wednesday, February 7, 2024 | |
Time: | 2:00 – 2:25 p.m. Eastern Standard Time (EST) | |
Moderator: | Seamus Fernandez | |
Location: |